Five years after the FDA formally rejected J&J’s Yondelis (trabectedin) for ovarian cancer, and three years after an aborted effort to get it back on track, the pharma giant has finally made its way back to the agency for another try at an approval–this time as a treatment for soft tissue sarcoma.

…read more

Source: J&J hopes third time is the charm for antitumor agent Yondelis


0 No comments